About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/20/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/20/2021.

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)

Clinicaltrials.gov identifier NCT03943602

Recruitment Status Recruiting

First Posted May 9, 2019

Last update posted October 21, 2019

Study Description

Brief summary:

Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)

  • Condition or Disease:Penile Squamous Cell Carcinoma
  • Intervention/Treatment: Drug: Cabozantinib
  • Phase: Phase 2
Detailed Description

an open-label, single-center, phase 2, single-arm trial

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 37 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)
  • Actual Study Start Date: August 2019
  • Estimated Primary Completion Date: June 2022
  • Estimated Study Completion Date: September 2022
Arms and interventions
Arm Intervention/treatment
Experimental: Cabozantinib
Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
Drug: Cabozantinib
Cabozantinib 60 mg/day orally
Outcome Measures
  • Primary Outcome Measures: 1. response -rate by RECIST v1.1 criteria [ Time Frame: 40 months ]
    Assessment of response-rate by RECIST v1.1. Complete response + partial response
  • Secondary Outcome Measures: 1. Incidence of treatment-Emergent Adverse Event(safety and tolerability) [ Time Frame: 40 months ]
    Assessment of the safety and tolerability: incidence, nature and severity of treatment-related adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
  • 2. Pathologic complete response (pCR) [ Time Frame: 40 months ]
    Histological report of radical surgery
  • 3. Progression-free survival (PFS). [ Time Frame: 40 months ]
    Recist 1.1 criteria
  • 4. Overall Survival (OS). [ Time Frame: 40 months ]
    time will be calculated as the interval from treatment start date to the date of death for any cause, with censoring at the date of last contact for patients alive.
  • 5. Variations of the Quality of Life [ Time Frame: 40 months ]
    Variations of the Quality of Life score as assessed with the Edmonton Symptom Assessment Scale (ESAS), validated in Italian language. In this quality of life there are specify 9 main symptons: the score range is from 0 to 10 for each one. For each symptom the "0 score" corrisponds to "no symptom present" (better outcome) and the "10 score" corrisponds to "maximum symptom assessable" (worse outcome). The listed symptoms are: 1) Pain 2) Fatigue 3) Nausea 4) Depression 5) Anxiety 6) Somnolence 7) Loss of appetite 8) General Malaise 9) Dispnea. The total score is ranging from 0 to 90
  • 6. FDG-PET/CT response rate according to EORTC criteria [ Time Frame: 40 months ]
    to determine the rate of concordance with CT scan RECIST 1.1 response criteria and PET/CT EORTC Criteria Complete response: complete disappearance of all target lesions with the exception of nodal disease (RECIST 1.1) and Complete resolution of FDG uptake in all lesions (EORTC) Partial response (PR): greater than or equal to 30% decrease under baseline of the sum of target lesions (RECIST 1.1) and ≥ 25% reduction in the sum of SUVmax Stable disease (SD): Not qualify for CR, PR or PD Objective Progression (PD): 20% increase in the sum of diameters of target lesions or appearance of new unequivocal malignant lesions (RECIST 1.1) and ≥ 25% Increase in the sum of SUVmax or appearance of new lesions. To evaluate the relationship existing between tumor response measured by FDG-PET/CT EORTC Criteria (mainly early PET response as evaluated at first restaging) and pCR-rate (pT0 after surgery) and progression-free survival (months).
Eligibility Criteria
  • Ages Eligible for Study: 18 to 75 Years (Adult, Older Adult)
  • Sexes Eligible for Study: Male
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Age 18-75

2. Written informed consent

3. ECOG (Eastern Cooperative Oncology Group) performance status 0-1

4. Cytologically or histologically proven diagnosis of PSCC.

5. Histologically (Tru-cut biopsy) proven diagnosis of loco-regional nodal disease will
be required in all cases except for those with clinical contraindications.

6. Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria.

7. Clinical stage N2-3 and/or M1 (TNM 2002).

8. Locoregional relapse after prior major surgery/ies (either single or multiple).

9. No prior systemic therapy except for the administration of VBM (Vinblastine,
Bleomycin, Methotrexate) chemotherapy for superficial disease if administered at least
6 months prior to study enrolment.

10. Adequate organ and marrow function .

11. Patients must be accessible for treatment and follow up as well as they must be
willing and capable to comply with the requirements of the study. Patients registered
on this trial must be treated and followed at the study sponsor site.

Exclusion Criteria:

1. History of any one or more of the following cardiovascular conditions within the past
6 months:

- Cardiac angioplasty or stenting.

- Myocardial infarction.

- Unstable angina.

- Coronary artery by-pass graft surgery.

- Symptomatic peripheral vascular disease.

- Class III or IV congestive heart failure, as defined by the New York Heart
Association (NYHA).

- Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin
are permitted during the study but should be used with caution - please refer to
the study drug IB).

- Screening ECG with a QTc>450 msec, congenital long QT syndrome, history of
sustained ventricular tachycardia, history of ventricular fibrillation or torsade
de pointes, bradycardia defined as heart rate 50 bpm are eligible).

- Uncontrolled hypertension.

2. History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure
medication for 6 months ior to first dose of study drug.

3. History of HIV infection or active chronic hepatitis B or C.

4. Active clinically serious infections (> grade 2 NCI-CTC version 5.0).

5. Patients with seizure disorder requiring medication (such as steroids or

6. Patients undergoing renal dialysis

7. Previous or concurrent cancer that is distinct in primary site or histology from the
cancer being evaluated in this study EXCEPT treated basal cell carcinoma or any cancer
curatively treated > 5 years prior to study entry.

8. History of clinically-significant gastrointestinal bleeding, inflammatory bowel
disease, and other GI disorders associated with high risk of perforation or fistula
formation or any other condition.

9. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
glucose-galactose malabsorption.

10. Major surgery within 12 weeks before the first dose of study treatment. Complete wound
healing from major surgery must have occurred 1 month before the first dose of study
treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days
before the first dose of study treatment with complete wound healing at least 10 days
before the first dose of study treatment. Subjects with clinically relevant ongoing
complications from prior surgery are not eligible.

11. History of allogenic organ solid transplantation.

12. Fertile males not willing to use a highly effective method of contraception or whose
female partner is not using a highly effective contraception protection.

13. Substance abuse, medical, psychological or social conditions that may interfere with
the patient's participation in the study or evaluation of the study results.

14. Any condition that is unstable or could jeopardize the safety of the patient and their
compliance in the study.

15. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to study drug.

16. Hemoptysis >=2.5 ml red blood within 3 months before treatment, signs indicative of
pulmonary hemorrhage, cavitating pulmonary lesion, tumor invading major blood vessels
and/or GI tract, endotracheal or endobronchial tumors History of
clinically-significant gastrointestinal bleeding, inflammatory bowel disease, or any
other condition among those listed in the full protocol.

17. Patients unable to swallow oral medications.

18. Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.

19. History of cerebrovascular accident, pulmonary embolism or untreated deep venous
thrombosis (DVT) within the past 6 months.

Contacts and Locations

Contact: Andrea Necchi, MD +390223902402 andrea.necchi@istitutotumori.mi.it

Contact: Michela Rizzuti, Dr.ssa +390223903067 michela.rizzuti@istitutotumori.mi.it


Fondazione IRCCS Istituto Nazionale dei Tumori

Sponsors and Collaborators

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano


Study Chair: Andrea Necchi, MD Fondazione IRCCS Istituto Nazionale Tumori

More Information